412 related articles for article (PubMed ID: 15780441)
1. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
[TBL] [Abstract][Full Text] [Related]
2. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
3. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
5. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
Epstein JE; Charoenvit Y; Kester KE; Wang R; Newcomer R; Fitzpatrick S; Richie TL; Tornieporth N; Heppner DG; Ockenhouse C; Majam V; Holland C; Abot E; Ganeshan H; Berzins M; Jones T; Freydberg CN; Ng J; Norman J; Carucci DJ; Cohen J; Hoffman SL
Vaccine; 2004 Apr; 22(13-14):1592-603. PubMed ID: 15068840
[TBL] [Abstract][Full Text] [Related]
7. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen.
Xie Y; Sun HX; Li D
Vaccine; 2009 Jan; 27(5):757-64. PubMed ID: 19041358
[TBL] [Abstract][Full Text] [Related]
8. [Cellular immune responses of recombinant hepatitis B (rHB) vaccine and HBsAG derived from Hansenula polymorpha cells].
Hu ZY; He P; Zhang R; Fang X; Zhu FC; Qiu SH; Li HM; Wang H; Liang ZL; Zhuang H
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jul; 29(7):706-11. PubMed ID: 19031766
[TBL] [Abstract][Full Text] [Related]
9. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
Walsh DS; Pichyangkul S; Gettayacamin M; Tongtawe P; Siegrist CA; Hansukjariya P; Kester KE; Holland CA; Voss G; Cohen J; Stewart AV; Miller RS; Ballou WR; Heppner DG
Am J Trop Med Hyg; 2004 May; 70(5):499-509. PubMed ID: 15155981
[TBL] [Abstract][Full Text] [Related]
11. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.
Rahman F; Dahmen A; Herzog-Hauff S; Böcher WO; Galle PR; Löhr HF
Hepatology; 2000 Feb; 31(2):521-7. PubMed ID: 10655280
[TBL] [Abstract][Full Text] [Related]
12. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.
Baldwin SL; Shaverdian N; Goto Y; Duthie MS; Raman VS; Evers T; Mompoint F; Vedvick TS; Bertholet S; Coler RN; Reed SG
Vaccine; 2009 Oct; 27(43):5956-63. PubMed ID: 19679214
[TBL] [Abstract][Full Text] [Related]
13. ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.
Pearse MJ; Drane D
Vaccine; 2004 Jun; 22(19):2391-5. PubMed ID: 15193400
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of the kinesis of immune responses in mice vaccinated by different kinds of recombinant hepatitis B vaccines].
Hu ZY; He P; Fang X; Qiu SH; Liang ZL; Li HM; Zhuang H
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):810-4. PubMed ID: 19103120
[TBL] [Abstract][Full Text] [Related]
15. Astragalus polysaccharides enhance the humoral and cellular immune responses of hepatitis B surface antigen vaccination through inhibiting the expression of transforming growth factor β and the frequency of regulatory T cells.
Du X; Chen X; Zhao B; Lv Y; Zhang H; Liu H; Chen Z; Chen Y; Zeng X
FEMS Immunol Med Microbiol; 2011 Nov; 63(2):228-35. PubMed ID: 22077226
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses.
Qiao M; Murata K; Davis AR; Jeong SH; Liang TJ
Hepatology; 2003 Jan; 37(1):52-9. PubMed ID: 12500188
[TBL] [Abstract][Full Text] [Related]
17. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
Ockenhouse CF; Angov E; Kester KE; Diggs C; Soisson L; Cummings JF; Stewart AV; Palmer DR; Mahajan B; Krzych U; Tornieporth N; Delchambre M; Vanhandenhove M; Ofori-Anyinam O; Cohen J; Lyon JA; Heppner DG;
Vaccine; 2006 Apr; 24(15):3009-17. PubMed ID: 16356603
[TBL] [Abstract][Full Text] [Related]
18. Cimetidine enhances immune response of HBV DNA vaccination via impairment of the regulatory function of regulatory T cells.
Wang J; Su B; Ding Z; Du X; Wang B
Biochem Biophys Res Commun; 2008 Aug; 372(3):491-6. PubMed ID: 18502198
[TBL] [Abstract][Full Text] [Related]
19. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
Ma R; Du JL; Huang J; Wu CY
Biochem Biophys Res Commun; 2007 Sep; 361(2):537-42. PubMed ID: 17662694
[TBL] [Abstract][Full Text] [Related]
20. Engineered promiscuous T helper peptides for the induction of immune responses.
Ruiz M; Llopiz D; Zabaleta A; Lasarte JJ; Borrás-Cuesta F; Sarobe P
Mol Immunol; 2007 Mar; 44(9):2205-12. PubMed ID: 17157914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
